129298-91-5
基本信息
O-(氯乙酰氨甲酰基)烟曲霉素醇
甲硫氨酸氨肽酶-2抑制剂(TNP-470)
TNP 470/O-(氯乙酰氨甲酰基)烟曲霉素醇
[(3R,4S,5S,6R)-5-甲氧基-4-[(2R,3R)-2-甲基-3-(3-甲基丁-2-烯基)环氧乙烷-2-基]-1-氧杂螺[2.5]辛烷-6-醇] N-(2-氯乙酰基)氨基甲酸酯
AGM-1470
NSC642492
O-Chloracetyl-carbamoyl fumagillol
O-(chloroacetylcarbamoyl)fumagillol
6-O-chloroacetylcarbamoylfumagillol
TNP-470 - CAS 129298-91-5 - Calbiochem
O-(chloroacetyl-carbaMoyl) fuMagillol,TNP-470
O-(CHLOROACETYLCARBAMOYL)FUMAGILLOLTNP-470 AGM-1470
(3R,4S,5S,6R)-5-Methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2
物理化学性质
| 熔点 | 90-93°C |
| 比旋光度 | D24 -46.6° (c = 0.44 in CHCl3) |
| 密度 | 1.26±0.1 g/cm3(Predicted) |
| 储存条件 | -20°C |
| 溶解度 | 二甲基亚砜：>15mg/mL |
| 酸度系数(pKa) | 7.19±0.46(Predicted) |
| 形态 | 白色至淡黄色固体 |
| 颜色 | 白色至淡黄色蜡状 |
| 稳定性 | 吸湿性 |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H315-H319-H335 |
| 防范说明 | P261-P305+P351+P338 |
| 危险品标志 | Xi |
| 危险类别码 | 36/37/38 |
| 安全说明 | 26 |
| WGK Germany | 2 |
O-(氯乙酰氨甲酰基)烟曲霉素醇价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/01/25 | HY-101932 | O-(氯乙酰氨甲酰基)烟曲霉素醇 TNP-470 | 129298-91-5 | 1 mg | 2800元 |
| 2024/01/25 | HY-101932 | O-(氯乙酰氨甲酰基)烟曲霉素醇 TNP-470 | 129298-91-5 | 5mg | 7900元 |
| 2023/03/20 | HY-101932 | O-(氯乙酰氨甲酰基)烟曲霉素醇 TNP-470 | 129298-91-5 | 10mg | 12800元 |
常见问题列表
methionine aminopeptidase-2, angiogenesis
No significant difference of apoptotic cell numbers is observed between cells treated with TNP-470 and the controls. The IC 50 s of TNP-470 are 16.86±0.9 µg/mL, 3.16±0.6 µg/mL and 1.78±0.8 µg/mL for KKU-M213 cells at 24, 48 and 72 h, respectively. The results show that TNP-470 significantly reduces the number of migrated cells and invaded cells as compare with the vehicle treated group. TNP-470 decreases the migrated cells of KKU-M213 to 26% and of KKU-M214 to 11% (P<0.01). Similarly, TNP-470 also significantly affects cell invasion, the number of invaded cells is reduced to 25% in KKU-M213 (P<0.01) and to 15% in KKU-M214 (P<0.01). The relative expressions of MMP2 , MMP9 and c-MYC in TNP-470 treated cells are significantly suppressed compare to the vehicle treated cells.
Treatment with TNP-470 attenuates (P<0.05) liver lipid accumulation compare to high fat fed (HFF) mice. By day 5, TNP-470 treated mice consume significantly less grams of high fat food than vehicle treated HFF mice. By day 15 of treatment, TNP-470 mice are consuming an equivalent number of calories to that of chow fed mice, despite the provision of high fat diet. Treatment with TNP-470 increases (P<0.05) expression of adipose tissue LPL mRNA, compare to chow-fed and high-fat fed controls. TNP-470 decreases energy intake and increases energy expenditure.